APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST

NCT06687070 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Platinum-resistant Recurrent Ovarian Cancer
Advanced Solid Tumor

Interventions

DRUG: APG -2449
DRUG: PLD

Sponsor

Ascentage Pharma Group Inc.